Torin 2(IC50=0.25 nM), a specific and effective mTOR inhibitor, is the 800-fold greater specific activity for mTOR than PI3K and improves pharmacokinetic properties. The EC50 of Torin 2 for ATM/ATR/DNA-PK inhibition is 28 nM/35 nM/118 nM, respectively.

PI3K:200 nM (EC50, cell assay), hVps34:8.58 nM, ATM:28 nM(EC50), p110γ:5.67 nM, PI3KC2β:24.5 nM, DNA-PK:118 nM(EC50), mTOR:0.25 nM, PI4KB:18.3 nM, ATR:35 nM(EC50), PI3KC2α:28.1 nM

mTOR and PI3K Cellular Assays: Cellular IC50 values for mTOR are determined using p53?/? MEFs. Cells are treated with vehicle or increasing concentrations of Torin 2 for 1 h and then lyse. Phosphorylation of S6K1 Thr-389 is monitored by immunoblotting using a phospho-specific antibody. Meanwhile, cellular IC50 values for PI3Ka are determined based on phosphorylation of Akt Thr-308 in p53?/?/mLST8?/? MEFs or human PC3 cells expressing the S473D mutant of Akt1.

For viability, MZ-CRC-1 and TT cells are seeded in quadruplicate in 96-well plates (1.0×104 cells per well) in culture media with 2.5% and 4% FBS, respectively. After 24 hours, cells are treated with Torin 2. At the indicated time point, cells are incubated for 3 hours with 10 μL of CellTiter96 AQueous One solution in 100 μL of culture media and absorbance is measured at 490 nm.(Only for Reference)